Artac, MehmetBozcuk, HakanKıyıcı, AyselEren, Orhan ÖnderBoruban, Melih CemÖzdoğan, Mustafa2020-03-262020-03-262013Artac, M., Bozcuk, H., Kıyıcı, A., Eren, O. O., Boruban, M. C., Özdoğan, M., (2013). Correlation of Serum Leptin Level and Waist-to-hip Ratio (WHR) With Overall Survival of Patients With Metastatic Breast Cancer (MBC) Treated With Aromatase Inhibitors (AIs). Journal of Clinical Oncology, (20), 174-180. Doi: 10.1007/s12282-011-0322-10732-183X1527-7755https://dx.doi.org/10.1007/s12282-011-0322-1https://hdl.handle.net/20.500.12395/24742Introduction Our objective was to determine whether serum leptin levels and obesity-related factors could affect outcome for metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs). Methods Sixty MBC patients treated with first line hormonal therapy were enrolled in this study. Results Median age was 51 years (range 28–75). Median leptin level was 19400 pg/ml (1970–91900) and estradiol level 29.6 pg/ml (4.0–181.9). Factors associated with overall survival in univariate analysis were age and waist-to-hip ratio (WHR), whereas only WHR retained significance in the multivariate analysis. However, no factor was associated with progression-free survival. However, WHR was found to be a significant prognostic marker only if the leptin level was C19400 pg/ml (HR = 0.38; 95% CI: 0.16–0.91). Conclusions This study suggests that serum leptin levels and WHR together may serve as potential prognostic markers in MBC patients treated with AIs.en10.1200/jco.2010.28.15_suppl.1106info:eu-repo/semantics/openAccessMetastatic breast cancerLeptinWaist-to-hip ratioWeightAromatase inhibitorsHormonal therapyConference Object20174180WOS:000208852002621Q1